Evidence map›Paper›PMID 31062041›Full record

Observational studyDiabetologia2019

Moderate weight change following diabetes diagnosis and 10 year incidence of cardiovascular disease and mortality.

Jean Strelitz, Amy L Ahern, Gráinne H Long, Matthew J L Hare, Greg Irving, Clare E Boothby, Nicholas J Wareham, Simon J Griffin

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Diabetologia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 5 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 5 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Perspectives on Stringent Glycemic Control and Weight Loss Among Patients with Type 2 Diabetes in China: A Survey Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Weight Change, Lifestyle, and Mortality in Patients With Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2022
    Observational
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Jean StrelitzMRC Epidemiology Unit, Institute of Metabolic Science, Cambridge Biomedical Campus, University of Cambridge School of Clinical Medicine, Box 285, Cambridge, CB2 0QQ, UK. jean.strelitz@mrc-epid.cam.ac.uk.ORCID 0000-0003-4051-6944
Amy L AhernMRC Epidemiology Unit, Institute of Metabolic Science, Cambridge Biomedical Campus, University of Cambridge School of Clinical Medicine, Box 285, Cambridge, CB2 0QQ, UK.
Gráinne H LongAstraZeneca Pharmaceuticals, Cambridge, UK.
Matthew J L HareDepartments of Endocrinology, Diabetes and Vascular Medicine, Monash Health, Melbourne, VIC, Australia.
Greg IrvingPrimary Care Unit, Institute of Public Health, University of Cambridge School of Clinical Medicine, Cambridge, UK.
Clare E BoothbyMRC Epidemiology Unit, Institute of Metabolic Science, Cambridge Biomedical Campus, University of Cambridge School of Clinical Medicine, Box 285, Cambridge, CB2 0QQ, UK.
Nicholas J WarehamMRC Epidemiology Unit, Institute of Metabolic Science, Cambridge Biomedical Campus, University of Cambridge School of Clinical Medicine, Box 285, Cambridge, CB2 0QQ, UK.
Simon J GriffinMRC Epidemiology Unit, Institute of Metabolic Science, Cambridge Biomedical Campus, University of Cambridge School of Clinical Medicine, Box 285, Cambridge, CB2 0QQ, UK.
University of Cambridge · GBAstraZeneca (United Kingdom) · GBMonash Health · AU

Funding

Department of Health 08/116/300Department of Health RP-PG-0606-1259Medical Research Council G0001164Medical Research Council MC_UU_12015/1Medical Research Council MC_UU_12015/4Wellcome TrustWellcome Trust G061895
6 · The paper itself

Abstract

aims/hypothesisAdults with type 2 diabetes are at high risk of developing cardiovascular disease (CVD). Evidence of the impact of weight loss on incidence of CVD events among adults with diabetes is sparse and conflicting. We assessed weight change in the year following diabetes diagnosis and estimated associations with 10 year incidence of CVD events and all-cause mortality.

methodsIn a cohort analysis among 725 adults with screen-detected diabetes enrolled in the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION)-Cambridge trial, we estimated HRs for weight change in the year following diabetes diagnosis and 10 year incidence of CVD (n = 99) and all-cause mortality (n = 95) using Cox proportional hazards regression. We used linear regression to estimate associations between weight loss and CVD risk factors. Models were adjusted for age, sex, baseline BMI, smoking, occupational socioeconomic status, cardio-protective medication use and treatment group.

resultsLoss of ≥5% body weight in the year following diabetes diagnosis was associated with improvements in HbA CONCLUSIONS/

interpretationAmong adults with screen-detected diabetes, loss of ≥5% body weight during the year after diagnosis was associated with a lower hazard of CVD events compared with maintaining weight. These results support the hypothesis that moderate weight loss may yield substantial long-term CVD reduction, and may be an achievable target outside of specialist-led behavioural treatment programmes.

Indexed as

Weight GainWeight LossAdultBody WeightCardiovascular DiseasesCluster AnalysisDenmarkDiabetes ComplicationsDiabetes Mellitus, Type 2EnglandFollow-Up StudiesHumansIncidenceNetherlandsObservational Studies as TopicPragmatic Clinical Trials as TopicCardiovascular diseaseDiabetesEpidemiologyWeight loss

Identifiers

PMID31062041
PMCPMC6647260
OpenAlexW2943997545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.